REG - Oxford Biomedica PLC - Half Year Trading Update

Oxford BioMedicaAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250728:nRSb6974Sa&default-theme=true

RNS Number : 6974S  Oxford Biomedica PLC  28 July 2025

 

Half Year Trading Update; strong start to FY 2025 with full year guidance
reiterated

 

-       Continued commercial, financial and operational momentum as OXB
executes on its multi-vector, multi-site strategy

 

-       H1 2025 revenues of £70-73 million, an increase of 38%-44% vs.
£51 million at H1 2024

 

-       Commercial momentum accelerating, with £149 million new
orders(1) signed during H1 2025, more than double the £56 million orders
signed during H1 2024

 

-       Full year 2025 guidance (CC(2)) reiterated: £160-170 million in
revenues and low single digit operating EBITDA(3) profitability

o  Over £165 million of 2025 revenues contracted vs. £103 million at H1
2024

 

-       Strong order book reinforcing confidence in both full year 2025
and medium-term revenue growth

o  Revenue backlog(4) of £222 million at 30 June 2025

 

-       The Company will announce its H1 2025 interim results on 23
September 2025 with a Capital Markets Day scheduled for 15 October 2025

 

Oxford, UK - 28 July 2025: OXB (LSE: OXB) ("the Company"), a global quality
and innovation-led cell and gene therapy CDMO, today provides a trading update
for the six months ended 30 June 2025.

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "With our
multi-vector, multi-site model now fully in place, our strong operational and
commercial progress continued in the first half of the year, reflecting both
our execution capabilities and the growing trust in OXB as a leading cell and
gene CDMO partner. Our order book has more than doubled year-on-year,
including notable growth in late-stage programme activity, demonstrating
strong demand for our services and providing long-term revenue visibility. As
we expand capacity to meet this growing demand, we remain focused on
operational excellence and cost discipline. With robust fundamentals in place
and clear visibility into the second half of the year, we remain confident in
our ability to deliver our full year guidance and achieve sustainable growth
in 2025 and beyond."

 

Strong first half performance; full year guidance reiterated

For the six months ended 30 June 2025, OXB expects to report revenues of
approximately £70-73 million, representing an increase of 38%-44% over H1
2024 revenues of £51 million. The Company reiterates full year 2025 revenue
guidance of £160-170 million (on a constant currency basis). Over £165
million of 2025 revenues are covered by contracted client orders, compared to
£103 million for the same period last year. This provides clear visibility
for the remainder of the year (subject to revenue performance obligations),
with revenues weighted to the second half, in line with prior years. Second
half revenue phasing includes an increase in manufacturing activity for
clients preparing for commercial launch.

 

With a continued focus on efficiency and a disciplined approach to cost
management, the Company continues to expect low single digit Operating EBITDA
profitability (on a constant currency basis) for the full year 2025. OXB's
cash position remains strong with gross cash of £53.9 million as of 30 June
2025.

 

Late-stage lentiviral programme demand driving strong commercial momentum

The contracted value of client orders signed during the first half of 2025
totalled approximately £149 million, compared to £56 million for the six
months ended 30 June 2024. This includes signed orders from clients preparing
for late-stage and commercial activities, providing strong visibility for the
remainder of 2025 and 2026. Revenue backlog stood at approximately £222
million as at 30 June 2025, compared to approximately £150 million as at 31
December 2024.

 

Demand for OXB's CDMO services remains strong, with consistent conversion
across all key vector types. The alignment of operations across the UK, the
US and France is increasing efficiency and agility, allowing OXB to support
clients across geographies and development stage. OXB is seeing increased
client demand from existing and new clients, particularly among clients
looking to accelerate execution of late-stage lentiviral programmes. AAV
client activity has also continued to grow in line with expectations.

 

Multi-vector, multi-site strategy delivering on plan

OXB's multi-vector, multi-site strategy continues to progress well, with
lentiviral vector manufacturing capabilities now available across its UK, US
and French sites. In June 2025, OXB completed the acquisition of the remaining
10% stake in its US subsidiary, OXB US LLC, from Q32 Bio, Inc. The site is
fully integrated into OXB's global network and together with its UK and France
operations, the Company is well positioned to provide global client support
across all major vector types and development stages.

 

Reflecting continued strong client demand for OXB's services, the Company is
proceeding with planned capacity management initiatives to accommodate current
and expected growth. This comprises:

i) an increase in GMP manufacturing capacity at OXB's UK sites, to be achieved
by refitting existing suites and modifying shift cadence, to be completed by
H1 2026; and

ii) expanding UK lab capacity for development services to support late-stage
client programme activities, including increasing the use of automation.

 

In addition, the Company has commenced transferring its AAV vector platform to
its sites in France, providing a unified global operation focused on
client-centric excellence. Process development and pilot manufacturing
capabilities for AAV are now available for clients in France, with transfer of
GMP capabilities targeted to be completed by the first half of 2026.

 

Notice of Results and Capital Markets Day

OXB will report its Interim Results for the six months ended 30 June 2025 on
23 September 2025. A briefing for investors and analysts will take place at
13:00 BST / 08:00 ET at RBC Capital Markets, 100 Bishopsgate, London, EC2N
4AA.

 

The Company also announces it will host a Capital Markets Day on 15 October
2025. Further details, including the agenda and how to register, will be
disclosed in due course.

 

For details of other upcoming financial events, please refer to the Company's
investor calendar at https://oxb.com/investor-events/.

 

(1)Contracted value of client orders represent the value of customer orders
for which the customer has signed a financial commitment, whereby any changes
to agreed values will be subject to either change orders, cancellation fees or
the triggering of optional/contingent contractual clauses.

 

(2)CC refers to Constant Currency, which refers to the equivalent growth based
on the prior year exchange rates.

 

(3)Operating EBITDA (Earnings Before Interest, Tax, Depreciation,
Amortisation, Impairment, revaluation of investments and assets at fair value
through profit and loss and share based payments).

( )

(4)Revenue backlog represents the ordered gross value of CDMO revenues
available to earn. The value of customer orders included in revenue backlog
only includes the value of work for which the customer has signed a financial
commitment for OXB to undertake, whereby any changes to agreed values will be
subject to change orders, cancellation fees or the triggering of
optional/contingent contractual clauses.

 

 

 

-Ends-

 

 

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), a dual-plasmid system for AAV production, suspension
and perfusion process using process enhancers and stable producer and
packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFIFFTDAIRFIE